Fig. 3: At a lower dose of irradiation (4*2 Gy), the olaparib and irradiation combination treatment is effective against subcutaneous tumours but not against orthotopic tumours. | British Journal of Cancer

Fig. 3: At a lower dose of irradiation (4*2 Gy), the olaparib and irradiation combination treatment is effective against subcutaneous tumours but not against orthotopic tumours.

From: Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models

Fig. 3

Subcutaneous (n = 7) (a) or orthotopic (n = 5–6) (b) LL2-luc tumours were allowed to grow. Then, the mice were randomised (day 1) and treated with olaparib (50 mg/kg) daily from day 1 to day 6, and irradiated (dose per fraction, 2 Gy) on days 1, 2, 4 and 5. Analyses of tumour growth (left panel), mouse survival (middle), body weight (right panel) and statistical analysis of mouse survival (bottom) are shown.

Back to article page